- RaniPill® HC achieved 4/4 successful drug delivery of orally administered Humira® (adalimumab) - - RaniPill® HC has achieved a cumulative >90% success rate across multiple preclinical studies – - RaniPill® HC shortlisted as a finalist by Fierce Life Sciences Innovation Awards – SAN JOSE, Calif., Oct.

-RaniPill®HC实现了口服Humira®（阿达木单抗）的4/4成功药物输送--RaniPill®HC在多项临床前研究中获得了累积>90%的成功率--RaniPill®HC被激烈的生命科学入围入围获奖者创新奖-加利福尼亚州圣何塞，Oct。

19, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the successful oral delivery of a monoclonal antibody, Humira® (adalimumab), via its high-capacity capsule, the RaniPill® HC, in a preclinical study.

192023年（GLOBE NEWSWIRE）-专注于口服生物制剂和药物的临床阶段生物治疗公司Rani Therapeutics Holdings，Inc.（“Rani Therapeutics”或“Rani”）（纳斯达克：Rani）今天宣布在临床前研究中通过其高容量胶囊RaniPill®HC成功口服递送单克隆抗体Humira®（阿达木单抗）。

“The preclinical results we are sharing today show the potential of the RaniPill® platform to orally deliver large molecules, such as antibodies, at high volume, which could enable the replacement of many injectable drugs with an oral pill,” said Mir Hashim, PhD, Chief Scientific Officer for Rani Therapeutics.

“我们今天分享的临床前结果显示了RaniPill®平台以高容量口服递送大分子（如抗体）的潜力，这可以用口服药丸替代许多可注射药物，”Mir Hashim博士说，Rani Therapeutics首席科学官。

“The high-capacity version, the RaniPill® HC, is capable of delivering up to a 500%-plus higher drug payload than Rani’s existing oral biologics capsule and has achieved a cumulative >90% success rate for delivery across multiple preclinical studies. The data generated to date with the RaniPill® HC give us confidence as we progress the high-capacity device towards clinical readiness.” Data Highlights Rani conducted a preclinical study tracking the serum concentrations of adalimumab, following the oral administration of the enteric-coated, RaniPill® HC capsule containing 11mg of Humira® (adalimumab) to four canine models.

“与Rani现有的口服生物制剂胶囊相比，高容量版本RaniPill®HC能够提供高达500%以上的药物有效载荷，并且在多项临床前研究中实现了累积>90%的成功率。RaniPill®HC迄今为止生成的数据使我们有信心，因为我们将高容量设备推向临床准备状态。“数据突出显示Rani进行了一项临床前研究，跟踪阿达木单抗的血清浓度，口服含有11mg Humira®（阿达木单抗）的肠溶衣RaniPill®HC胶囊至四种犬模型。

The RaniPill® HC successfully delivered adalimumab in all of the subjects. All device remnants were excreted normally without sequelae. Rani has orally administered the RaniPill® HC .

RaniPill®HC在所有受试者中成功递送阿达木单抗。所有设备残留物均正常排泄，无后遗症。Rani口服了RaniPill®HC。